Regina Salvat

Regina Salvat is a Principal at Forbion based in Boston, Massachusetts, where she focuses on private and crossover investments in the biotechnology sector. Before joining the firm in March 2025, she spent five years at Sofinnova Investments, executing therapeutics transactions and collaborating on deals involving Capstan Therapeutics, Gyroscope Therapeutics, and Aiolos Bio. Her operational and strategic experience includes prior corporate roles at Rubius Therapeutics and Pfizer, as well as serving as a board director for Pionyr and a current board member for Marea Therapeutics. Salvat earned a doctorate in protein engineering from Dartmouth College between 2010 and 2014, following her bachelor's and master's degrees in biomedical engineering from Cornell University. Her career centers on leveraging her advanced scientific training to identify and scale emerging therapeutic platforms within the global life sciences venture capital ecosystem.